ATR and small cell lung carcinoma: Part of this signature is the ATR pathway which showed a highly enriched score in Pure-LCC, suggesting a central distinctive activity of this pathway, thus paving the way for innovative therapeutic perspectives in Pure-LCC including the use of Berzosertib, an ATR inhibitor, tested in combination with topotecan in patients affected by platinum-resistant SCLC [21].